RT Journal Article
T1 Fecal microbiota transplantation in HIV: A pilot placebo-controlled study
A1 Serrano-Villar, Sergio
A1 Talavera-Rodríguez, Alba
A1 Gosalbes, María José
A1 Madrid, Nadia
A1 Pérez-Molina, José Antonio
A1 Elliott, Ryan J
A1 Navia Lombán, Beatriz
A1 Lanza, Val F
A1 Vallejo, Alejandro
A1 Osman, Majdi
A1 Dronda, Fernando
A1 Budree, Shrish
A1 Zamora, Javier
A1 Gutiérrez, Carolina
A1 Manzano, Mónica
A1 Vivancos, María Jesús
A1 Ron, Raquel
A1 Martínez-Sanz, Javier
A1 Herrera, Sabina
A1 Ansa, Uxua
A1 Moya, A
A1 Moreno, Santiago
AB Changes in the microbiota have been linked to persistent inflammation during treated HIV infection. In this pilot double-blind study, we study 30 HIV-infected subjects on antiretroviral therapy (ART) with a CD4/CD8 ratio < 1 randomized to either weekly fecal microbiota capsules or placebo for 8 weeks. Stool donors were rationally selected based on their microbiota signatures. We report that fecal microbiota transplantation (FMT) is safe, not related to severe adverse events, and attenuates HIV-associated dysbiosis. FMT elicits changes in gut microbiota structure, including significant increases in alpha diversity, and a mild and transient engraftment of donor’s microbiota during the treatment period. The greater engraftment seems to be achieved by recent antibiotic use before FMT. The Lachnospiraceae and Ruminococcaceae families, which are typically depleted in people with HIV, are the taxa more robustly engrafted across time-points. In exploratory analyses, we describe a significant amelioration in the FMT group in intestinal fatty acid-binding protein (IFABP), a biomarker of intestinal damage that independently predicts mortality. Gut microbiota manipulation using a non-invasive and safe strategy of FMT delivery is feasible and deserves further investigation. Trial number: NCT03008941.
PB Springer Nature
YR 2021
FD 2021-02-18
LK https://hdl.handle.net/20.500.14352/93106
UL https://hdl.handle.net/20.500.14352/93106
LA eng
NO Serrano-Villar S, Talavera-Rodríguez A, Gosalbes MJ, Madrid N, Pérez-Molina JA, Elliott RJ, Navia B, Lanza VF, Vallejo A, Osman M, Dronda F, Budree S, Zamora J, Gutiérrez C, Manzano M, Vivancos MJ, Ron R, Martínez-Sanz J, Herrera S, Ansa U, Moya A, Moreno S. Fecal microbiota transplantation in HIV: A pilot placebo-controlled study. Nat Commun. 2021 Feb 18;12(1):1139.
NO Instituto de Salud Carlos III
NO SPANISH AIDS Research Network
NO European Development Regional Fund ‘A way to achieve Europe’ (ERDF)
NO Fundación Asociación Española contra el Cáncer
NO Fundación Española para la Ciencia y la Tecnología(FECYT)
NO Finch Therapeutics
DS Docta Complutense
RD 5 abr 2025